🚨 BREAKING: Moderna $MRNA JUST EXPLODED 130%!
Its personalized mRNA cancer vaccine, developed with Merck, delivered a HISTORIC Phase 3 win in high-risk melanoma.
The treatment met its main goal of reducing cancer recurrence AND its secondary goal of reducing the risk of the cancer spreading.
The trial included 1,137 patients and tested Moderna’s Intismeran alongside Merck’s Keytruda.
This is the FIRST positive Phase 3 result for an mRNA cancer vaccine.
Moderna may have just opened the door to an entirely new era of personalized cancer treatment.
The full data is still to come, but Wall Street is already pricing in massive potential for the technology beyond melanoma.
#Moderna #MRNA #Cancer #Biotech #Stocks $MRNA.US
Its personalized mRNA cancer vaccine, developed with Merck, delivered a HISTORIC Phase 3 win in high-risk melanoma.
The treatment met its main goal of reducing cancer recurrence AND its secondary goal of reducing the risk of the cancer spreading.
The trial included 1,137 patients and tested Moderna’s Intismeran alongside Merck’s Keytruda.
This is the FIRST positive Phase 3 result for an mRNA cancer vaccine.
Moderna may have just opened the door to an entirely new era of personalized cancer treatment.
The full data is still to come, but Wall Street is already pricing in massive potential for the technology beyond melanoma.
#Moderna #MRNA #Cancer #Biotech #Stocks $MRNA.US